WMCHealth cancer profiling will use Philips IntelliSpace Genomics to integrate genomic sequencing analysis with complete patient data to tailor treatment in New York’s Hudson Valley.
Amsterdam, the Netherlands and Valhalla, NY – Royal Philips (NYSE: PHG; AEX: PHIA) and the Westchester Medical Center Health Network (WMCHealth), the leading provider of advanced medical care in New York’s Hudson Valley, today announced the launch of WMCHealth’s new precision medicine initiative for personalized cancer treatment, which will use Philips’ IntelliSpace Genomics solution to integrate large-scale genomic analysis with extensive patient clinical data.
WMCHealth leverages Philips IntelliSpace Genomics to combine the output from next-generation sequencing (NGS) with clinical data and advanced information sharing, to provide a comprehensive patient view for precision-tailored treatment. With base operations at its flagship Westchester Medical Center, the WMCHealth precision medicine initiative will be available to all hospitals in the WMCHealth Network as well as other facilities in the Hudson Valley and beyond.
Philips’ IntelliSpace Genomics is a configurable, scalable and secure health informatics solution across hospitals for delivering real-time, actionable diagnostic information to physicians and specialists for therapy planning at the point of care. Philips IntelliSpace Genomics’ collaborative solution enables physicians to answer key clinical questions by leveraging the best clinical expertise and algorithmic power in integrated workflows. It seamlessly brings data from multiple sources – including raw sequencing data, up-to-date in silico genomic databases, clinical data and knowledge databases, longitudinal patient records, medical images and pathology data, among others.
“Our team at WMCHealth sees and treats the most complex cancer cases. Our new precision medicine platform for oncology is designed to leverage all available sources of critical information to help make the most informed decisions about each patient’s care,” said John Fallon, MD, PhD, Director, Department of Clinical Pathology, , Westchester Medical Center, and Chairman of Pathology, New York Medical College “WMCHealth’s new cancer diagnostic program gives us greater capabilities to test and validate clinical planning, through the fusion of highly specific and individualized patient information with massive and growing genomic knowledge of cancer.”
Dr. Fallon added, “The Philips IntelliSpace Genomics solution is a foundation for designing possible therapy plans in a digital framework, such as how to match a tumor’s genotype with a potential drug for the best outcome, for example, or matching patients with clinical trials. This is a powerful tool to help improve outcomes through precision medicine.”
The genomics project is part of a larger investment by WMCHealth into groundbreaking diagnostic and treatment capabilities, including WMCHealth’s new Cellular & Tissue Engineering Laboratory (CTEL), home to state-of the-art technology that facilitates cellular therapy under investigational new drug applications in support of treatments for a variety of hematological and oncological disorders and diseases.
The IntelliSpace Genomics solution can be configured to define new workflows, create new pipelines, or integrate new sources of data as required, and can be used for collaborative clinical analysis and sharing across multiple hospitals and their affiliates, either on-site or in the cloud.
The Philips’ IntelliSpace Genomics solution is built on Philips HealthSuite, a cloud-enabled connected health ecosystem of devices, apps and digital tools that work seamlessly together to enable personalized integrated health and continuous care.
“As the number of targeted cancer drugs and clinical trials continue to expand, it is critical to give clinicians insight into genetic mutations driving a particular patient’s cancer, along with the complete patient context of diagnostic tests and medical history to enable a precise focus on personalized treatment,” said Louis Culot, General Manager of Philips Genomics.
Culot noted, “The new WMCHealth platform leverages Philips IntelliSpace Genomics’ informatics capabilities to help achieve this, as well to as provide physicians with a networked solution that offers a single integrated interface for collaboration between doctors and institutions.”
AND
Philips teams up with Molecular decision support leader N-of-One to speed up clinical interpretation of cancer genomics
• Alliance aims to fortify precision medicine oncology decision support for clinicians
• Philips IntelliSpace Genomics solution leverages N-of-One’s extensive and variant database and interpretation solutions to extend the reach and scale of personalized medicine
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, and N-of-One, Inc., the leader in clinical interpretation of molecular tests in oncology, today announced they are teaming up to enhance the capabilities of Philips’ IntelliSpace Genomics solution. The two companies will collaborate on the clinical analysis, annotation and interpretation of oncology cases processed through Philips new precision medicine solution for oncology. This healthcare informatics solution integrates genomic information with full patient context to empower clinicians with precision diagnostics and therapeutics, to enable them to measure the success of precision healthcare programs.
Profiling tumors using genomic information is critical for complex cancer cases, yet challenges remain in rapidly and accurately interpreting genomic findings in the context of a patient’s condition. While most cancer patients have thousands of gene variants and mutations, only a small number actually drive the individual’s specific cancer or may have actionable therapeutic implications for a particular patient.
The Philips IntelliSpace Genomics solution, which uniquely integrates complete patient information, is coupled with N-of-One’s rich experience and extensive knowledge-bases. For the first time, clinicians will have full access to N-of-One’s variant database during the case filtering and interpretation process, providing them ready access to the vast amount of available reference literature, guidelines, and evidence, in a fully interactive framework. The aim is to help clinicians determine which treatment options, clinical trials or medications, are best suited to a specific case.
“N-of-One has been a pioneer in the field, and by integrating their information directly on our IntelliSpace Genomics solution, we aim to reduce the turn-around time for these cancer cases”, said Louis Culot, General Manager, Philips Genomics. “Providing specialists with the most relevant treatment options through the analysis of each patient’s unique molecular profile will help extend the reach and scale of personalized medicine.”
“Philips is a clear leader in clinical informatics, integrating and managing big data in the healthcare settings,” said Chris Cournoyer, CEO of N-of-One. “We believe that incorporating N-of-One’s Variant Database along with its patient case analysis and interpretation services will be further enabled by tight integration with this leading digital health solution.”
In addition to integrating and processing genomic information from an array of high-throughput platforms, IntelliSpace Genomics provides full traceability of data processing and cases for unprecedented reproducibility and audit of interpretation and results. Uniquely, it can also leverage existing patient information available in healthcare settings including past treatment history and lab results, while providing analytics to empower precision healthcare decision support.
Earlier today, Philips and Westchester Medical Center (WMCHealth) announced the launch of WMCHealth’s new precision medicine initiative for personalized cancer treatment, which will use Philips’ IntelliSpace Genomics solution to integrate large-scale genomic analysis with extensive patient clinical data. The WMCHealth precision medicine initiative will be covering 15 hospitals and oncology practices in the New York Metro area and Hudson Valley.
